Drug news
NICE recommends Pradaxa for Stroke Prevention in non vavular atrial fibrillation patients
NICE has made a final appraisal determination that recommends the direct thrombin inhibitor Pradaxa (dabigatran etexilate) from Boehringer as an option for preventing stroke and systemic embolism in patients with nonvalvular atrial fibrillation with one or more of the following risk factors �previous stroke, transient ischaemic attack or systemic embolism;
�left ventricular ejection fraction below 40%;
�symptomatic heart failure of New York Heart Association (NYHA) class 2 or above;
�age 75 years or older;
�age 65 years or older with diabetes mellitus, coronary artery disease or hypertension.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins